|Product Candidate / Program||Drug substance||Indication||Discovery||Pre-clinical||Phase I||Phase II||Phase III / Pivotal|
|ERYZYME||Therapeutic enzymes||Metabolic diseases|
ERYZYME is the latest Erytech’s preclinical program dedicated to Enzyme based therapies therapy (ERT), a medical strategy consisting in the administration of enzymes to patients in whom it is deficient or absent.
Since most of diseases caused by enzyme deficiencies are from genetic origin, ERT, when available, consists in life-long multiple administrations of exogenous enzymes, eventually leading to immune reactions that affect the efficacy of the therapy. Based on the data obtained with our leading product eryaspase, the encapsulation of ERT-enzymes in erythrocytes should extend their lifetime in blood circulation, thus reducing the need for frequent administrations as well as the occurrence of immune reactions.